Healthcare
Name:
Sector:
Diacrin
Healthcare
Summary:
Diacrin developed cell transplantation technology for treating human diseases characterized by cell dysfunction or cell death and for which current therapies are either inadequate or nonexistent.
Stage of Initial
Investment:
Venture
Liquidity:
Merged with Genvec (Nasdaq: GNVC)
Copyright ©2009 Rho Capital Partners, Inc.
